A Multidomain Prediction Model Integrating Myocardial Injury, Ventricular Function, and Inflammation for Short-Term Risk Stratification in Patients with NSTEMI
Authors:
Open Access
- 4 August 2026
- journal article
- research article
- Published by MDPI AG in Clinics and Practice
- Vol. 16 (8) , 143
Abstract
Background/Objectives: Early risk stratification remains challenging in patients with non-ST-segment elevation myocardial infarction (NSTEMI). The present study evaluated the prognostic value of 24 h high-sensitivity cardiac troponin I (hs-Troponin I) and assessed whether combining biomarkers and echocardiographic parameters improves short-term risk prediction. Methods: This prospective observational cohort study included 170 consecutive adult patients with confirmed NSTEMI who were admitted to a Medical Intensive Care Unit and prospectively enrolled between February 2022 and January 2023. Clinical, routine biochemical, inflammatory, hematological, lipid, and echocardiographic data were collected during index hospitalization. High-sensitivity cardiac troponin I was measured at admission and again 24 h after hospitalization, with the 24 h value used as the principal marker of myocardial injury in the prediction analyses. The primary endpoint was major adverse cardiovascular events (MACEs), defined as cardiovascular death, recurrent myocardial infarction, ischemic stroke, urgent coronary revascularization, or hospitalization for worsening heart failure, within 3 months. Multivariable logistic regression, Cox regression, sequential prediction modeling, and internal bootstrap validation were performed. Results: MACEs occurred in 88 patients (51.8%). Twenty-four-hour hs-Troponin I, but not admission hs-Troponin I, was independently associated with MACEs (OR 1.57, 95% CI 1.09–2.26; p = 0.015) and a shorter time to the first MACE event (HR 1.38, 95% CI 1.07–1.78; p = 0.012). Lower left ventricular ejection fraction (LVEF) was also independently associated with adverse outcomes. The addition of 24 h hs-Troponin I, LVEF, and C-reactive protein improved discrimination from an AUC of 0.665 to 0.759 (optimism-corrected AUC, 0.717), with corresponding improvements in reclassification. A simplified multimarker score was independently associated with event-free survival (HR 2.36, 95% CI 1.53–3.64; p < 0.001). Conclusions: In patients admitted to a medical intensive care unit with NSTEMI, the integration of 24 h hs-Troponin I, LVEF, and C-reactive protein improved short-term risk prediction beyond that of clinical variables alone. A practical multimarker model based on routinely available parameters identified patients at increased risk of adverse cardiovascular outcomes during early follow-up.Keywords
This publication has 26 references indexed in Scilit:
- Differences in the characteristics and outcomes of STEMI versus NSTEMI cardiogenic shock: A systematic review and meta-analysisMedicine, 2025
- Inflammatory markers guide early risk stratification and prognosis in elderly patients with acute myocardial infarctionScientific Reports, 2025
- Advancements in Biomarkers for Early Detection and Risk Stratification of Cardiovascular Diseases—A Literature ReviewHealth Science Reports, 2025
- The effect of inflammatory markers on mortality in patients with acute myocardial infarctionScientific Reports, 2025
- Non–ST‐Segment–Elevation Myocardial Infarction: When Is Rapid Revascularization Critical?Journal of the American Heart Association, 2021
- Association Between Intensive Care Unit Usage and Long‐Term Medication Adherence, Mortality, and Readmission Among Initially Stable Patients With Non–ST‐Segment–Elevation Myocardial InfarctionJournal of the American Heart Association, 2020
- Association between reduced left ventricular ejection fraction following non-ST-segment elevation myocardial infarction and long-term mortality in patients of advanced ageInternational Journal of Cardiology, 2019
- Multimarker Risk Stratification in Patients With Acute Myocardial InfarctionJournal of the American Heart Association, 2016
- The "smoker's paradox" in patients with acute coronary syndrome: a systematic reviewBMC Medicine, 2011
- C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart StudyCirculation: Cardiovascular Quality and Outcomes, 2008